Baxter Kidney Care is Now Vantive, A New Standalone Vital Organ Therapy Company
Vantive builds on a 70-year legacy of kidney care leadership and innovation, with a singular focus on empowering patients and care teams with more flexible, collaborative and accessible care options
With over 1 million daily interactions with patients across more than 100 countries, Vantive exists to extend lives and expand possibilities for patients everywhere
DEERFIELD, Ill., Feb. 03, 2025 (GLOBE NEWSWIRE) — Vantive, formerly the Baxter Kidney Care segment, today launched as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle (NASDAQ: CG) from Baxter International Inc. (NYSE: BAX). Vantive builds on a 70-year legacy as a leader in kidney care innovation to advance its mission of extending lives and expanding possibilities.
As an independent company, Vantive is dedicated to elevating the standards of kidney and vital organ therapies with a vision to enable longer, fuller lives for patients everywhere. Approximately 4 million people worldwide receive dialysis treatment for chronic kidney disease.1 Access to this life-sustaining treatment varies across regions, and patients on dialysis often face physical and emotional burdens throughout the therapy process. Empowering patients and care teams, while helping to break down the barriers to starting and staying on therapy, is central to Vantive’s strategy to advance vital organ therapies.
“From patients beginning their dialysis journeys to clinicians fighting to save lives in the ICU, accessing the right therapy at the right time is critical. This is why our singular focus as Vantive is to empower more patients and care teams in these moments – with better options, greater control and expanded possibilities,” said Chris Toth, CEO of Vantive. “We are beginning a new era of vital organ therapy innovation, and I am looking forward to working with our 23,000 global Vantive colleagues to make a difference for millions of patients and families around the world.”
The Vantive Difference
Vantive delivers innovative products, digitally-enhanced solutions and advanced services to support dialysis at home and in the clinic, as well as critical care therapy to support the kidney and other vital organs in an intensive care unit (ICU) setting. Patients across more than 100 countries around the world interact with Vantive’s people, solutions and services over 1 million times each day. This represents over 1 million opportunities to impact the patient experience every day.
Through its fully integrated approach to innovation, Vantive seeks to help therapy fit more easily into providers’ practices and patients’ lives. Vantive’s technologies and solutions are designed to elevate the therapy experience, expand efficiencies for care teams, and enhance outcomes for patients. For example, the use of Vantive’s remote patient monitoring technology has been associated with lower incidence of all-cause mortality, fewer hospitalizations, reduced treatment drop-out, and greater treatment adherence for home dialysis.2
link